tradingkey.logo

Lyra Therapeutics Inc <LYRA.OQ> expected to post a loss of 14 cents a share - Earnings Preview

ReutersMay 7, 2025 11:01 AM
  • Lyra Therapeutics Inc LYRA.OQ LYRA.O is expected to show a fall in quarterly revenue when it reports results for the period ending June 30 2025

  • The Watertown Massachusetts-based company is expected to report a 59.5% decrease in revenue to $242 thousand from $598 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Lyra Therapeutics Inc is for a loss of 14 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had fallen by about 18.8% in the last three months. ​

  • Wall Street's median 12-month price target for Lyra Therapeutics Inc is $2.00​, above​ its last closing price of $0.10. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.15

-0.14

-0.12

Beat

12.2

Dec. 31 2025

-0.13

-0.12

-0.16

Missed

-33.3

Sep. 30 2024

-0.21

-0.23

-0.18

Beat

21.1​

Jun. 30 2024

-0.33

-0.33

-0.74

Missed

-125.6

​​Mar. 31 2024

-0.27

-0.26

-0.35

Missed

-33.6

Dec. 31 2023

-0.31

-0.22

Beat

30.2​

Sep. 30 2023

-0.31

-0.32

-0.27

Beat

15.1

Jun. 30 2023

-0.40

-0.42

-0.32

Beat

24.4

This summary was machine generated May 7 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI